Paper Details

  1. Home
  2. Paper Details

The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.

Author: JennerPeter, KandaTomoyuki, Kawai-UchidaMika, MoriAkihisa, OkitaEri, SoshirodaKazuhiro, UchidaShin-ichi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated whether istradefylline administered with a threshold dose of either the non-ergot dopamine agonist, ropinirole or the ergot dopamine agonist, pergolide enhances anti-parkinsonian activity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmoset.
Paper Details　
Original Abstract of the Article :
The adenosine A2A receptor antagonist, istradefylline, enhances anti-parkinsonian activity in patients with advanced Parkinson׳s disease (PD) already treated with combinations of L-DOPA and dopamine agonist drugs but who are still exhibiting prolonged 'OFF' periods. In contrast, the effects of istra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejphar.2014.11.038

データ提供：米国国立医学図書館（NLM）

Istradefylline: A New Hope for Parkinson's Disease Treatment

Parkinson's disease, a neurodegenerative disorder, can significantly impact a person's mobility and quality of life. This research explores the potential benefits of combining istradefylline, an adenosine A2A receptor antagonist, with low doses of dopamine agonists in treating Parkinson's disease. They conducted a study with common marmosets with Parkinson's disease, investigating the effects of istradefylline in combination with dopamine agonists on motor function and dyskinesia.

A Promising Combination for Parkinson's

The study found that combining istradefylline with low doses of dopamine agonists improved motor function and increased 'ON' time in common marmosets with Parkinson's disease. This suggests that this combination therapy may be a promising approach for treating Parkinson's disease, particularly in early stages.

Hope for Parkinson's Patients

This research offers hope for patients with Parkinson's disease, suggesting a potential treatment strategy that could improve motor function and reduce the need for high doses of dopamine agonists. The findings encourage further investigation into the long-term effects and safety of this combination therapy. It is like a camel discovering a hidden spring in the desert, providing a source of refreshment and hope for the journey ahead.

Dr.Camel's Conclusion

This research explores the potential of combining istradefylline with low doses of dopamine agonists in treating Parkinson's disease. The study demonstrates that this combination therapy may be a promising approach for improving motor function and reducing the need for high doses of dopamine agonists, offering hope for patients with Parkinson's disease.

Date :
  1. Date Completed 2015-10-26
  2. Date Revised 2015-01-26
Further Info :

Pubmed ID

25499739

DOI: Digital Object Identifier

10.1016/j.ejphar.2014.11.038

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.